US OptionsDetailed Quotes

MYGN241220C16000

Watchlist

0.85
0.000.00%

15min DelayClose Nov 22 16:00 ET

0.00High0.00Low

Myriad Genetics Stock Discussion

Trytosaveabit

Mar 20 15:22

Bad sign when a patent granted gets zero attention!

$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE

Moomoo AI

Feb 1 08:31

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 30 16:00

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Moomoo AI

Jan 18 17:37

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

Press Release: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 2 06:32

The low P/S ratio for Myriad Genetics is likely due to its subpar revenue performance and limited future growth expectations, which have suppressed its share price. These conditions could hinder a significant rise in the share price in the near future.

Investors Aren't Buying Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues

Moomoo AI

Nov 10, 2023 13:15

Though Myriad Genetics maintains a cash surplus, doubt arises from its lack of free cash flow, negative EBIT, and significant liabilities.

Is Myriad Genetics (NASDAQ:MYGN) Using Too Much Debt?

Moomoo AI

Nov 1, 2023 08:08

CEO Paul Diaz is confident in Raha's capability to enhance profitability and expand the company, leveraging his substantial experience in diagnostics. Diaz considers Raha will introduce new ideas and expertise to progress current business missions and operational excellence.

Press Release: Myriad Genetics Appoints Sam Raha as Chief Operating Officer

ETFWorldSavior

Sep 20, 2023 01:44

Columns Myriad Genetics: improving financial profile

Goldman Sachs were very encouraged by the presentation and lab tour at the Investor Day. While the stock could benefit from a clean quarter where the improved organic growth profile is highlighted, the market should be ascribing more credit to the transformation in the business over the past few years. Goldman see an improving financial profile as previous investments in commercial, revenue cycle management, lab automation and R&D contribute to growth...

Moomoo Breakfast US

Jul 13, 2022 08:04

Columns Today's pre-market stock movers: TWTR, U, SFIX, ILMN and more

Gainers:
• $ironSource (IS.US)$ +65% (Unity (U) confirms merger agreement with ironSource)
• $Stitch Fix (SFIX.US)$ +8% (director purchases 1 mln shares)
• $Wallbox (WBX.US)$ +7.4% (Wallbox and Svea Solar announce a new partnership to integrate solar and EV charging)
• $Myriad Genetics (MYGN.US)$ +5.2% (new study by VA shows Major Depressive Disorder remission rates were significantly improved with GeneSight)
• $Golub Capital BDC (GBDC.US)$...

No comment yet